Handelsbanken Fonder Ab Supernus Pharmaceuticals, Inc. Transaction History
Handelsbanken Fonder Ab
- $26.2 Billion
- Q4 2024
A detailed history of Handelsbanken Fonder Ab transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 19,116 shares of SUPN stock, worth $617,255. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,116
Previous 17,216
11.04%
Holding current value
$617,255
Previous $537,000
28.68%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SUPN
# of Institutions
302Shares Held
60.7MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$336 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$199 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$156 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$92.9 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$84.9 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.73B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...